Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance.
COVID-19
Molnupiravir
Omicron
Real-world experience
SARS-CoV-2
Treatment
Journal
Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
28
06
2022
accepted:
17
08
2022
revised:
12
08
2022
pubmed:
25
8
2022
medline:
15
12
2022
entrez:
24
8
2022
Statut:
ppublish
Résumé
The real-world effectiveness of molnupiravir (MOL) during the dominance of Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the period of circulation of other viral variants. Therefore, this study assessed the efficacy of MOL in patients hospitalized for COVID-19 in a real-world clinical practice during the wave of Omicron infections. Among 11,822 patients hospitalized after 1 March 2020 and included in the SARSTer national database, 590 were treated between 1 January and 30 April 2022, a period of dominance of the Omicron SARS-CoV-2 variant. MOL was administered to 203 patients, whereas 387 did not receive any antiviral regimen. Both groups were similar in terms of sex, BMI and age allowing for direct comparisons. Patients who did not receive antiviral therapy significantly more often required the use of Dexamethasone and Baricitinib. Treatment with MOL resulted in a statistically significant reduction in mortality during the 28-day follow-up (9.9 vs. 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of the disease (14.6 vs. 35.2%). MOL therapy did not affect the frequency of the need for mechanical ventilation, but patients treated with MOL required oxygen supplementation less frequently than those without antivirals (31.7 vs. 49.2%). The time of hospitalization did not differ between groups. The use of molnupiravir in patients hospitalized for COVID-19 during the dominance of Omicron variant reduced mortality. This effect is particularly evident in patients over 80 years of age.
Sections du résumé
BACKGROUND
BACKGROUND
The real-world effectiveness of molnupiravir (MOL) during the dominance of Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the period of circulation of other viral variants. Therefore, this study assessed the efficacy of MOL in patients hospitalized for COVID-19 in a real-world clinical practice during the wave of Omicron infections.
METHODS
METHODS
Among 11,822 patients hospitalized after 1 March 2020 and included in the SARSTer national database, 590 were treated between 1 January and 30 April 2022, a period of dominance of the Omicron SARS-CoV-2 variant. MOL was administered to 203 patients, whereas 387 did not receive any antiviral regimen. Both groups were similar in terms of sex, BMI and age allowing for direct comparisons.
RESULTS
RESULTS
Patients who did not receive antiviral therapy significantly more often required the use of Dexamethasone and Baricitinib. Treatment with MOL resulted in a statistically significant reduction in mortality during the 28-day follow-up (9.9 vs. 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of the disease (14.6 vs. 35.2%). MOL therapy did not affect the frequency of the need for mechanical ventilation, but patients treated with MOL required oxygen supplementation less frequently than those without antivirals (31.7 vs. 49.2%). The time of hospitalization did not differ between groups.
CONCLUSIONS
CONCLUSIONS
The use of molnupiravir in patients hospitalized for COVID-19 during the dominance of Omicron variant reduced mortality. This effect is particularly evident in patients over 80 years of age.
Identifiants
pubmed: 36001284
doi: 10.1007/s43440-022-00408-6
pii: 10.1007/s43440-022-00408-6
pmc: PMC9400562
doi:
Substances chimiques
molnupiravir
YA84KI1VEW
Hydroxylamines
0
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1279-1285Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Mader A-L, Tydykov L, Glück V, Bertok M, Weidlich T, Gottwald C, et al. Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. IScience. 2022;25: 104076.
doi: 10.1016/j.isci.2022.104076
Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198: 105252.
doi: 10.1016/j.antiviral.2022.105252
Rahmah L, Abarikwu SO, Arero AG, Jibril AT, Fal A, Flisiak R, et al. Oral antiviral treatments for COVID-19: opportunities and challenges. Rep: Pharmacol; 2022. https://doi.org/10.1007/s43440-022-00388-7 .
Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol. 2021;50:17–22.
doi: 10.1016/j.coviro.2021.06.003
Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH 3rd, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451–7.
doi: 10.1038/s41586-021-03312-w
Kumarasamy N, Jindal, A, Saha, B, Singh VB, Rodduturi NCR, Sinha S, Sriramadasu SC. Phase III trial of molnupiravir in adults with mild SARS-cov2 infection in India. In: CROI Virtual Conference, Denver 2022, abstract #101
Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297: 100770.
doi: 10.1016/j.jbc.2021.100770
Jayk BA, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–20.
doi: 10.1056/NEJMoa2116044
Arribas JR, Bhagani S, Lobo SM, Khaertynova I, Mateu L, Fishchuk R, et al. Randomized trial of molnupiravir or placebo in patients hospitalized with covid-19. NEJM Evid. 2022. https://doi.org/10.1056/evidoa2100044 .
doi: 10.1056/evidoa2100044
Flisiak R, Horban A, Jaroszewicz J, Kozielewicz D, Mastalerz-Migas A, Owczuk R, et al. Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021. Pol Arch Intern Med. 2021;131:487–96. https://doi.org/10.20452/pamw.16140 .
doi: 10.20452/pamw.16140
Flisiak R, Horban A, Jaroszewicz J, Kozielewicz D, Mastalerz-Migas A, Owczuk R, et al. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022. Pol Arch Intern Med. 2022. https://doi.org/10.20452/pamw.16230 .
doi: 10.20452/pamw.16230
MI2DataLab. Monitor of SARS-CoV-2. 2022. https://monitor.crs19.pl/2022-03-31/poland/?lang=en . Accessed June 23 2022.
Flisiak R, Zarębska-Michaluk D, Berkan-Kawińska A, Tudrujek-Zdunek M, Rogalska M, Piekarska A, et al. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study. Pol Arch Intern Med. 2021;131:103–10.
Zarębska-Michaluk D, Jaroszewicz J, Rogalska M, Martonik D, Pabjan P, Berkan-Kawińska A, et al. Effectiveness of tocilizumab with and without dexamethasone in patients with severe COVID-19: a retrospective study. J Inflamm Res. 2021;14:3359–66.
doi: 10.2147/JIR.S322645
Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA.2 wave: an observational study. BioRxiv. 2022. https://doi.org/10.1101/2022.05.19.22275291 .
doi: 10.1101/2022.05.19.22275291